HMGA and Cancer

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 1-2, 2010, Pages 48-54

  Fedele, Monica ^a,b   Fusco, Alfredo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Carcinogenesis; Chromatinic protein; High Mobility Group protein; Mesenchymal tumor; Pituitary adenomas

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN;

APOPTOSIS; BENIGN TUMOR; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; GENE CONTROL; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SILENCING; GENE TARGETING; HUMAN; HYPOPHYSIS ADENOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 74849129422     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.11.007     Document Type: Review

References (121)

1. Thanos D., and Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71 (1992) 777-789
2. Thanos D., Du W., and Maniatis T. The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb. Symp. Quant. Biol. 58 (1993) 73-81
3. Reeves R., and Nissen M.S. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J. Biol. Chem. 265 (1990) 8573-8582
4. Sgarra R., Maurizio E., Zammitti S., Lo Sardo A., Giancotti V., and Manfioletti G. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J. Proteome Res. 8 (2009) 2789-2978
5. Zhou X., Benson K.F., Ashar H.R., and Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376 (1995) 771-774
6. Chiappetta G., Avantaggiato V., Visconti R., Fedele M., Battista S., Trapasso F., Merciai B.M., Fidanza V., Giancotti V., Santoro M., Simeone A., and Fusco A. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13 (1996) 2439-2446
7. Rommel B., Rogalla P., Jox A., Kalle C.V., Kazmierczak B., Wolf J., and Bullerdiek J. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk. Lymphoma 26 (1997) 603-607
8. Anand A., and Chada K. In vivo modulation of Hmgic reduces obesity. Nat. Genet. 24 (2000) 377-380
9. Nishino J., Kim I., Chada K., and Morrison S.J. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 135 (2008) 227-239
10. Battista S., Fidanza V., Fedele M., Klein-Szanto A.J., Outwater E., Brunner H., Santoro M., Croce C.M., and Fusco A. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res. 59 (1999) 4793-4797
11. Fedele M., Fidanza V., Battista S., Pentimalli F., Klein-Szanto A.J., Visone R., De Martino I., Curcio A., Morisco C., Del Vecchio L., Baldassarre G., Arra C., Viglietto G., Indolfi C., Croce C.M., and Fusco A. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 66 (2006) 2536-2543
12. Foti D., Chiefari E., Fedele M., Iuliano R., Brunetti L., Paonessa F., Manfioletti G., Barbetti F., Brunetti A., Croce C.M., Fusco A., and Brunetti A. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med. 11 (2005) 765-773
13. Chiefari E., Paonessa F., Iiritano S., Le Pera I., Palmieri D., Brunetti G., Lupo A., Colantuoni V., Foti D., Gulletta E., De Sarro G., Fusco A., and Brunetti A. The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biol. 7 (2009) 24-37
14. Sreekantaiah C., Leong S.P., Karakousis C.P., McGee D.L., Rappaport W.D., Villar H.V., Neal D., Fleming S., Wankel A., Herrington P.N., Carmona R., and Sandberg A.A. Cytogenetic profile of 109 lipomas. Cancer Res. 51 (1991) 422-433
15. Schoenmakers E.F., Wanschura S., Mols R., Bullerdiek J., Van den Berghe H., and Van de Ven W.J. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat. Genet. 10 (1995) 436-444
16. Ashar H.R., Fejzo M.S., Tkachenko A., Zhou X., Fletcher J.A., Weremowicz S., Morton C.C., and Chada K. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82 (1995) 57-65
17. Ligon A.H., Moore S.D., Parisi M.A., Mealiffe M.E., Harris D.J., Ferguson H.L., Quade B.J., and Morton C.C. Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. Am. J. Hum. Genet. 76 (2005) 340-348
18. Buysse K., Reardon W., Mehta L., Costa T., Fagerstrom C., Kingsbury D.J., Anadiotis G., McGillivray B.C., Hellemans J., de Leeuw N., de Vries B.B., Speleman F., Menten B., and Mortier G. The 12q14 microdeletion syndrome: additional patients and further evidence that HMGA2 is an important genetic determinant for human height. Eur. J. Med. Genet. 52 (2009) 101-107
19. Weedon M.N., Lettre G., Freathy R.M., Lindgren C.M., Voight B.F., Perry J.R., Elliott K.S., Hackett R., Guiducci C., Shields B., Zeggini E., Lango H., Lyssenko V., Timpson N.J., Burtt N.P., Rayner N.W., Saxena R., Ardlie K., Tobias J.H., Ness A.R., Ring S.M., Palmer C.N., Morris A.D., Peltonen L., Salomaa V., Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium, Davey Smith G., Groop L.C., Hattersley A.T., McCarthy M.I., Hirschhorn J.N., and Frayling T.M. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat. Genet. 39 (2007) 1245-1250
20. Weedon M.N., Lango H., Lindgren C.M., Wallace C., Evans D.M., Mangino M., Freathy R.M., Perry J.R., Stevens S., Hall A.S., Samani N.J., Shields B., Prokopenko I., Farrall M., Dominiczak A., Diabetes Genetics Initiative, Wellcome Trust Case Control Consortium, Johnson T., Bergmann S., Beckmann J.S., Vollenweider P., Waterworth D.M., Mooser V., Palmer C.N., Morris A.D., Ouwehand W.H., Cambridge GEM Consortium, Zhao J.H., Li S., Loos R.J., Barroso I., Deloukas P., Sandhu M.S., Wheeler E., Soranzo N., Inouye M., Wareham N.J., Caulfield M., Munroe P.B., Hattersley A.T., McCarthy M.I., and Frayling T.M. Genome-wide association analysis identifies 20 loci that influence adult height. Nat. Genet. 40 (2008) 575-583
21. Sanna S., Jackson A.U., Nagaraja R., Willer C.J., Chen W.M., Bonnycastle L.L., Shen H., Timpson N., Lettre G., Usala G., Chines P.S., Stringham H.M., Scott L.J., Dei M., Lai S., Albai G., Crisponi L., Naitza S., Doheny K.F., Pugh E.W., Ben-Shlomo Y., Ebrahim S., Lawlor D.A., Bergman R.N., Watanabe R.M., Uda M., Tuomilehto J., Coresh J., Hirschhorn J.N., Shuldiner A.R., Schlessinger D., Collins F.S., Davey Smith G., Boerwinkle E., Cao A., Boehnke M., Abecasis G.R., and Mohlke K.L. Common variants in the GDF5-UQCC region are associated with variation in human height. Nat. Genet. 40 (2008) 198-203
22. Tallini G., Vanni R., Manfioletti G., Kazmierczak B., Faa G., Pauwels P., Bullerdiek J., Giancotti V., Van Den Berghe H., and Dal Cin P. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab. Invest. 80 (2000) 359-369
23. Tallini G., Dal Cin P., Rhoden K.J., Chiappetta G., Manfioletti G., Giancotti V., Fusco A., Van den Berghe H., and Sciot R. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am. J. Pathol. 151 (1997) 37-43
24. Medeiros F., Erickson-Johnson M.R., Keeney G.L., Clayton A.C., Nascimento A.G., Wang X., and Oliveira A.M. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. Genes Chromosomes Cancer 46 (2007) 981-990
25. Kazmierczak B., Wanschura S., Rommel B., Bartnitzke S., and Bullerdiek J. Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings. J. Natl. Cancer Inst. 88 (1996) 1234-1236
26. Staats B., Bonk U., Wanschura S., Hanisch P., Schoenmakers E.F., Van de Ven W.J., Bartnitzke S., and Bullerdiek J. A fibroadenoma with a t(4;12) (q27;q15) affecting the HMGI-C gene, a member of the high mobility group protein gene family. Breast Cancer Res. Treat. 38 (1996) 299-303
27. Dal Cin P., Wanschura S., Kazmierczak B., Tallini G., Dei Tos A., Bullerdiek J., Van den Berghe I., Moerman P., and Van den Berghe H. Amplification and expression of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer 22 (1998) 95-99
28. Persson F., Andrén Y., Winnes M., Wedell B., Nordkvist A., Gudnadottir G., Dahlenfors R., Sjögren H., Mark J., and Stenman G. High-resolution genomic profiling of adenomas and carcinomas of the salivary glands reveals amplification, rearrangement, and fusion of HMGA2. Genes Chromosomes Cancer 48 (2009) 69-82
29. Nucci M.R., Weremowicz S., Neskey D.M., Sornberger K., Tallini G., Morton C.C., and Quade B.J. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer 32 (2001) 172-176
30. Geurts J.M., Schoenmakers E.F., Roijer E., Stenman G., and Van de Ven W.J. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res. 57 (1997) 13-17
31. Takahashi T., Nagai N., Oda H., Ohama K., Kamada N., and Miyagawa K. Evidence for RAD51L1/HMGIC fusion in the pathogenesis of uterine leiomyoma. Genes Chromosomes Cancer 30 (2001) 196-201
32. Mine N., Kurose K., Konishi H., Araki T., Nagai H., and Emi M. Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma. Jpn. J. Cancer Res. 92 (2001) 135-139
33. Crombez K.R., Vanoirbeek E.M., Van de Ven W.J., and Petit M.M. Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol. Cancer Res. 3 (2005) 63-70
34. Xiao S., Lux M.L., Reeves R., Hudson T.J., and Fletcher J.A. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am. J. Pathol. 150 (1997) 901-910
35. Dal Cin P., Wanschura S., Christiaens M.R., Van den Berghe I., Moerman P., Polito P., Kazmierczak B., Bullerdiek J., and Van den Berghe H. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer 20 (1997) 90-92
36. Kazmierczak B., Dal Cin P., Wanschura S., Borrmann L., Fusco A., Van den Berghe H., and Bullerdiek J. HMGY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Gene Chromosomes Cancer 23 (1998) 279-285
37. Kazmierczak B., Meyer-Bolte K., Tran K.H., Wöckel W., Breightman I., Rosigkeit J., Bartnitzke S., and Bullerdiek J. A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer 26 (1999) 125-133
38. Lee Y.S., and Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21 (2007) 1025-1030
39. Mayr C., Hemmann M.T., and Bartel D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315 (2007) 1576-1579
40. Hebert C., Norris K., Scheper M.A., Nikitakis N., and Sauk J.J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular Cancer 6 (2007) 5-16
41. Kaddar T., Rouault J.P., Chien W.W., Chebel A., Gadoux M., Salles G., Ffrench M., and Magaud J.P. Two new miR-16 targets: Caprin-1 and HMGA1, proteins implicated in cell proliferation. Biol. Cell (2009 Feb 27) [Electronic publication ahead of print]
42. Fedele M., Berlingieri M.T., Scala S., Chiariotti L., Viglietto G., Rippel V., Bullerdiek J., Santoro M., and Fusco A. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17 (1998) 413-418
43. Wang X., Hulshizer R.L., Erickson-Johnson M.R., Flynn H.C., Jenkins R.B., Lloyd R.V., and Oliveira A.M. Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3′ UTR is not critical for HMGA2 transcriptional upregulation. Genes Chromosomes Cancer 48 (2009) 673-678
44. Hodge J.C., Cuenco K.T., Huyck K.L., Somasundaram P., Panhuysen C.I., Stewart E.A., and Morton C.C. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum. Genet. 125 (2009) 257-263
45. Arlotta P., Tai A.K., Manfioletti G., Clifford C., Jay G., and Ono S.J. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J. Biol. Chem. 275 (2000) 14394-14400
46. Fedele M., Battista S., Kenyon L., Baldassarre G., Fidanza V., Klein-Szanto A.J., Parlow A.F., Visone R., Pierantoni G.M., Outwater E., Santoro M., Croce C.M., and Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21 (2002) 3190-3198
47. Fedele M., Pentimalli F., Baldassarre G., Battista S., Klein-Szanto A.J., Kenyon L., Visone R., De Martino I., Ciarmiello A., Arra C., Viglietto G., Croce C.M., and Fusco A. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer lymphomas. Oncogene 24 (2005) 3427-3435
48. Finelli P. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Res. 62 (2002) 2398-2405
49. Pierantoni G.M., Finelli P., Valtorta E., Giardino D., Rodeschini O., Esposito F., Losa M., Fusco A., and Larizza L. High-mobility group A2 gene expression is frequently induced in non-functioning pituitary adenomas (NFPAs), even in the absence of chromosome 12 polysomy. Endocr. Relat. Cancer 12 (2005) 867-874
50. De Martino I., Visone R., Wierinckx A., Palmieri D., Ferraro A., Cappabianca P., Chiappetta G., Forzati F., Lombardi G., Colao A., Trouillas J., Fedele M., and Fusco A. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res. 69 (2009) 1844-1850
51. Bottoni A., Piccin D., Tagliati F., Luchin A., Zatelli M.C., and degli Uberti E.C. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell Physiol. 204 (2005) 280-285
52. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., Ciarmiello A., Pallante P., Arra C., Melillo R.M., Helin K., Croce C.M., and Fusco A. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 9 (2006) 459-471
53. De Martino I., Visone R., Palmieri D., Cappabianca P., Chieffi P., Forzati F., Barbieri A., Kruhoffer M., Lombardi G., Fusco A., and Fedele M. The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. Endocr. Relat. Cancer 14 (2007) 875-886
54. Andrieux J., Geffroy S., Bilhou-Nabera C., Dupriez B., Demory J.L., Bauters F., Laï J.L., and Dastugue N. Cryptic 6p21.3 duplications and triplication involving HMGA1 partially masked by add 6p in four cases of myelodysplasia. Cancer Gene Cytogenet. 164 (2006) 84-87
55. Odero M.D., Grand F.H., Iqbal S., Ross F., Roman J.P., Vizmanos J.L., Andrieux J., Laï J.L., Calasanz M.J., and Cross N.C. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia 19 (2005) 245-252
56. Giancotti V., Berlingieri M.T., DiFiore P.P., Fusco A., Vecchio G., and Crane-Robinson C. Changes in nuclear proteins following transformation of rat thyroid epithelial cells by a murine sarcoma retrovirus. Cancer Res. 45 (1985) 6051-6057
57. Giancotti V., Pani B., D'Andrea P., Berlingieri M.T., Di Fiore P.P., Fusco A., Vecchio G., Philp R., Crane-Robinson C., Nicolas R.H., et al. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c- myc and polyoma middle T genes. EMBO J. 6 (1987) 1981-1987
58. Giancotti V., Buratti E., Perissin L., Zorzet S., Balmain A., Portella G., Fusco A., and Goodwin G.H. Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp. Cell Res. 184 (1989) 538-545
59. Chiappetta G., Tallini G., De Biasio M.C., Manfioletti G., Martinez-Tello F.J., Pentimalli F., de Nigris F., Mastro A., Botti G., Fedele M., Berger N., Santoro M., Giancotti V., and Fusco A. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 58 (1998) 4193-4198
60. Chiappetta G., Ferraro A., Vuttariello E., Monaco M., Galdiero F., De Simone V., Califano D., Pallante P., Botti G., Pezzullo L., Pierantoni G.M., Santoro M., and Fusco A. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Europ. J. Cancer 44 (2008) 1015-1021
61. Abe N., Watanabe T., Sugiyama M., Uchimura H., Chiappetta G., Fusco A., and Atomi Y. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res. 59 (1999) 1169-1174
62. Chiappetta G., Manfioletti G., Pentimalli F., Abe N., Di Bonito M., Vento M.T., Giuliano A., Fedele M., Viglietto G., Santoro M., Watanabe T., Giancotti V., and Fusco A. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int. J. Cancer 91 (2001) 147-151
63. Balcerczak M., Pasz-Walczak G., Balcerczak E., Wojtylak M., Kordek R., and Mirowski M. HMGI(Y) gene expression in colorectal cancer: comparison with some histological typing, grading, and clinical staging. Pathol. Res. Pract. 199 (2003) 641-646
64. Abe N., Watanabe T., Masaki T., Mori T., Sugiyama M., Uchimura H., Fujioka Y., Chiappetta G., Fusco A., and Atomi Y. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 60 (2000) 3117-3122
65. Liau S.S., Rocha F., Matros E., Redston M., and Whang E. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 113 (2008) 302-314
66. Hristov A.C., Cope L., Reyes M.D., Singh M., Iacobuzio-Donahue C., Maitra A., and Resar L.M. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod. Pathol. 22 (2009) 43-49
67. Chiappetta G., Botti G., Monaco M., Pasquinelli R., Pentimalli F., Di Bonito M., D'Aiuto G., Fedele M., Iuliano R., Palmieri E.A., Pierantoni G.M., Giancotti V., and Fusco A. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin. Cancer Res. 10 (2004) 7637-7644
68. Sarhadi V.K., Wikman H., Salmenkivi K., Kuosma E., Sioris T., Salo J., Karjalainen A., Knuutila S., and Anttila S. Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 209 (2006) 206-212
69. Meyer B., Loeschke S., Schultze A., Weigel T., Sandkamp M., Goldmann T., Vollmer E., and Bullerdiek J. HMGA2 overexpression in non-small cell lung cancer. Mol. Carcinog. 46 (2007) 503-511
70. Nam E.S., Kim D.H., Cho S.J., Chae S.W., Kim H.Y., Kim S.M., Han J.J., Shin H.S., and Park Y.E. Expression of HMGI(Y) associated with malignant phenotype of human gastric tisse. Histopathology 42 (2003) 466-471
71. Motoyama K., Inoue H., Nakamura Y., Uetake H., Sugihara K., and Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin. Cancer Res. 14 (2008) 2334-2340
72. Masciullo V., Baldassarre G., Pentimalli F., Berlingieri M.T., Boccia A., Chiappetta G., Palazzo J., Manfioletti G., Giancotti V., Viglietto G., Scambia G., and Fusco A. HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24 (2003) 1191-1198
73. Bandiera A., Bonifacio D., Manfioletti G., Mantovani F., Rustighi A., Zanconati F., Fusco A., Di Bonito L., and Giancotti V. Expression of high mobility group I (HMGI) proteins in squamous intraepithelial lesions (SILs) of uterine cervix. Cancer Res. 58 (1998) 426-431
74. Abe N., Watanabe T., Izumisato Y., Suzuki Y., Masaki T., Mori T., Sugiyama M., Fusco A., and Atomi Y. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J. Gastroenterol. 38 (2003) 1144-1149
75. Chuma M., Saeki N., Yamamoto Y., Ohta T., Asaka M., Hirohashi S., and Sakamoto M. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J. Med. 53 (2004) 90-97
76. Chang Z.G., Yang L.Y., Wang W., Peng J.X., Huang G.W., Tao Y.M., and Ding X. Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker. Dig. Dis. Sci. 50 (2005) 1764-1770
77. Tamimi Y., van der Poel H.G., Denyn M.M., Umbas R., Karthaus H.F., Debruyne F.M., and Schalken J.A. Increased expression of high mobility group protein I (Y) in high grade prostate cancer determined by in situ hybridization. Cancer Res. 53 (1993) 5512-5516
78. Miyazawa J., Mitoro A., Kawashiri S., Chada K.K., and Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 64 (2004) 2024-2029
79. Rho Y.S., Lim Y.C., Park I.S., Kim J.H., Ahn H.Y., Cho S.J., and Shin H.S. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol. 127 (2007) 76-81
80. Giannini G., Cerignoli F., Mellone M., Massimi I., Ambrosi C., Rinaldi C., Dominici C., Frati L., Screpanti I., and Gulino A. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res. 65 (2005) 8308-8316
81. Donato G., Martinez Hoyos J., Amorosi A., Maltese L., Lavano A., Volpentesta G., Signorelli F., Pentimalli F., Pallante P., Ferraro G., Tucci L., Signorelli C.D., Viglietto G., and Fusco A. High mobility group A1 expression correlates with the histological grade of human glial tumors. Oncol. Rep. 11 (2004) 1209-1213
82. Akai T., Ueda Y., Sasagawa Y., Hamada T., Date T., Katsuda S., Iizuka H., Okada Y., and Chada K. High mobility group I-C protein in astrocytoma and glioblastoma. Pathol. Res. Pract. 200 (2004) 619-624
83. Berlingieri M.T., Manfioletti G., Santoro M., Bandiera A., Visconti R., Giancotti V., and Fusco A. Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol. Cell. Biol. 15 (1995) 1545-1553
84. Berlingieri M.T., Pierantoni G.M., Giancotti V., Santoro M., and Fusco A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21 (2002) 2971-2980
85. Scala S., Portella G., Fedele M., Chiappetta G., and Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4256-4261
86. Wood L.J., Maher J.F., Bunton T.E., and Resar L.M. The oncogenic properties of the HMG-I gene family. Cancer Res. 60 (2000) 4256-4261
87. Reeves R., Edberg D.D., and Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell Biol. 21 (2001) 575-594
88. Liau S.S., Jazag A., Ito K., and Whang E.E. Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells. Br. J. Cancer 96 (2007) 993-1000
89. Di Cello F., Hillion J., Hristov A., Wood L.J., Mukherjee M., Schuldenfrei A., Kowalski J., Bhattacharya R., Ashfaq R., and Resar L.M. HMGA2 participates in transformation in human lung cancer. Mol. Cancer Res. 6 (2008) 743-750
90. Watanabe S., Ueda Y., Akaboshi S., Hino Y., Sekita Y., and Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 174 (2009) 854-868
91. Baldassarre G., Fedele M., Battista S., Vecchione A., Klein-Szanto A.J., Santoro M., Waldmann T.A., Azimi N., Croce C.M., and Fusco A. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7970-7975
92. Zaidi M.R., Okada Y., and Chada K.K. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res. 66 (2006) 7453-7459
93. Xu Y., Sumter T.F., Bhattacharya R., Tesfaye A., Fuchs E.J., Wood L.J., Huso D.L., and Resar L.M. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res. 64 (2004) 3371-3375
94. Visone R., Iuliano R., Palmieri D., Server I.N., Chiappetta G., De Martino I., Fedele M., Costinean S., Oberyszyn T.M., Kusewitt D.F., Croce C.M., and Fusco A. Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis. Eur. J. Cancer 44 (2008) 318-325
95. Cleynen, Huysmans I.C., Sasazuki T., Shirasawa S., Van de Ven W., and Peeters K. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression. Cancer Res. 15 (2007) 4620-4629
96. Ferguson M., Henry P.A., and Currie R.A. Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res. 31 (2003) 3123-3133
97. Boyerinas B., Park S.M., Shomron N., Hedegaard M.M., Vinther J., Andersen J.S., Feig C., Xu J., Burge C.B., and Peter M.E. Identification of let-7-regulated oncofetal genes. Cancer Res. 68 (2008) 2587-2591
98. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., and Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131 (2007) 1109-1123
99. De Martino I., Visone R., Fedele M., Petrocca F., Palmieri D., Martinez Hoyos J., Forzati F., Croce C.M., and Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene 28 (2009) 1432-1442
100. Tessari M.A., Gostissa M., Altamura S., Sgarra R., Rustighi A., Salvagno C., Caretti G., Imbriano C., Mantovani R., Del Sal G., Giancotti V., and Manfioletti G. Transcriptional activation of the cyclin A gene by architectural transcriptional factor HMGA2. Mol. Cell. Biol. 23 (2003) 9104-9116
101. Vallone D., Battista S., Pierantoni G.M., Fedele M., Casalino L., Santoro M., Viglietto G., Fusco A., and Verde P. Neoplastic transformation of rat thyroid cells requires the JunB and Fra1 gene induction which is dependent on the HMGI-C gene products. EMBO J. 17 (1997) 5310-5321
102. Pierantoni G.M., Rinaldo C., Esposito F., Mottolese M., Soddu S., and Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ. 13 (2006) 1554-1563
103. Pierantoni G.M., Rinaldo C., Mottolese M., Di Benedetto A., Esposito F., Soddu S., and Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J. Clin. Invest. 117 (2007) 693-702
104. Subramanian D., and Griffith J.D. Interactions between p53, hMSH2-hMSH6 and HMGI(Y) on Holliday junctions and bulged bases. Nucl. Acids Res. 30 (2002) 2427-2434
105. Borrmann L., Schwanbeck R., Heyduk T., Seebeck B., Rogalla P., Bullerdiek J., and Wisniewski J.R. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucl. Acids Res. 31 (2003) 6841-6851
106. Baldassarre G. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell Biol. 23 (2003) 2225-2238
107. Reeves R., and Adair J.E. Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA Repair (Amst.) 4 (2005) 926-938
108. Pentimalli F., Palmieri D., Pacelli R., Garbi C., Cesari R., Martin E., Pierantoni G.M., Chieffi P., Croce C.M., Costanzo V., Fedele M., and Fusco A. HMGA1 protein is a novel target of the ATM kinase. Eur. J. Cancer 44 (2008) 2668-2679
109. Perrella M.A., Pellacani A., Wiesel P., Chin M.T., Foster L.C., Ibanez M., Hsieh C.M., Reeves R., Yet S.F., and Lee M.E. High mobility group-I(Y) protein facilitates nuclear factor-kappaB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer. J. Biol. Chem. 274 (1999) 9045-9052
110. Himes S.R., Coles L.S., Reeves R., and Shannon M.F. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 5 (1996) 479-489
111. Mantovani F., Covaceuszach S., Rustighi A., Sgarra R., Heath C., Goodwin G.H., and Manfioletti G. NF-kappaB mediated transcriptional activation is enhanced by the architectural factor HMGI-C. Nucleic Acids Res. 26 (1998) 1433-1439
112. Zhang X.M., and Verdine G.L. A small region in HMG I(Y) is critical for cooperation with NF-kappaB on DNA. J. Biol. Chem. 274 (1999) 20235-20243
113. Hillion J., Dhara S., Sumter T.F., Mukherjee M., Di Cello F., Belton A., Turkson J., Jaganathan S., Cheng L., Ye Z., Jove R., Aplan P., Lin Y.W., Wertzler K., Reeves R., Elbahlouh O., Kowalski J., Bhattacharya R., and Resar L.M. Thee high-mobility group A1a/signal transducer and activator of transcription-3 axis: an Achilles heel for hematopoietic malignancies. Cancer Res. 68 (2008) 10121-10127
114. Martinez Hoyos J., Ferraro A., Sacchetti S., Keller S., De Martino I., Borbone E., Pallante P., Fedele M., Montanaro D., Esposito F., Cserjesi P., Chiariotti L., Troncone G., and Fusco A. HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas. Oncogene 28 (2009) 876-885
115. Thuault S., Valcourt U., Petersen M., Manfioletti G., Heldin C.H., and Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell. Biol. 174 (2006) 175-183
116. Thuault S., Tan E.J., Peinado H., Cano A., Heldin C.H., and Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J. Biol. Chem. 283 (2008) 33437-33446
117. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., and Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 2257-2261
118. Pallante P., Federico A., Berlingieri M.T., Bianco M., Ferraro A., Forzati F., Iaccarino A., Russo M., Pierantoni G.M., Leone V., Sacchetti S., Troncone G., Santoro M., and Fusco A. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 68 (2008) 6770-6778
119. Liau S.S., and Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res. 14 (2008) 1470-1477
120. Kim M.P., and Gallick G.E. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin. Cancer Res. 14 (2008) 1284-1285
121. Summer H., Li O., Bao Q., Zhan L., Peter S., Sathiyanathan P., Henderson D., Klonisch T., Goodman S.D., and Dröge P. HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res. (2009 May 21) [Electronic publication ahead of print]